Intellectual Property India Publishes Patent Application for 'Fused Tricyclic Parp1 Inhibitor, Preparation Method Therefor, And Use Thereof' Filed by Haihe Biopharma Co. Ltd.

MUMBAI, India, June 27 -- Intellectual Property India has published a patent application (202517054883 A) filed by Haihe Biopharma Co. Ltd., Shanghai, on June 6, for 'fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof.'

Inventor(s) include Gao, Shanyun; Hou, Yingjie; Li, Jingjing; Zhang, Chaobo; Xu, Yanxiao; Tu, Wangyang; Yu, Bing; Zhang, Yixiang; and Li, Leping.

The application for the patent was published on June 27, under issue no. 26/2025.

According to the abstract released by the Intellectual Property India: "The present invention relates to a fused tricyclic PARP1 inhibitor, a preparation method therefor, and a use thereof. In particular, the present invention relates to a compound capable of inhibiting poly ADP-ribose polymerase activity, and a pharmaceutical composition and use thereof. The present invention relates in particular to compounds of formula (I), and also to pharmaceutical compositions comprising these compounds and to the use of these compounds in the preparation of a medicament for the prevention and/or treatment of a disease, in particular, diseased that can be ameliorated by inhibiting PARP1."

The patent application was internationally filed on Nov. 10, 2023, under International application No.PCT/CN2023/130888.

Disclaimer: Curated by HT Syndication.